Aignostics – a global AI company that turns complex multi-modal pathology data into transformative insights – announced that it has raised $34 million in Series B financing. This additional funding will be used for building new product offerings for biopharmaceutical clients, driving growth within the US and developing leading foundation models for pathology in collaboration with the Mayo Clinic. This oversubscribed funding round was led by ATHOS, with investments from Mayo Clinic and growth financing from HTGF, along with support from existing investors Wellington Partners, Boehringer Ingelheim Venture Fund, CARMA Fund, and VC Fonds Technologie managed by IBB Ventures.
Agnostics has raised over $55 million, reflecting investor confidence in its differentiated AI models and clear commercial strategy. And as precision medicine becomes more nuanced and complex, biopharmaceutical companies are increasingly turning to AI to enhance the utility, performance, and scalability of computational pathology analyses for drug development and diagnostics. In parallel, machine learning technologies are rapidly evolving – creating AI models with record accuracy, opening new avenues for biopharmaceutical research and diagnostics.
This new funding will strengthen Aignostics’ offerings for target ID, translational research, and companion diagnostics (CDx), and support several strategic initiatives, including:
1.) Launch of scaled “plug-and-play” products for a range of indications and tasks, including tumor microenvironment and biomarker profiling.
2.) A continued expansion into the US with additional headcount and support for US partners.
3.) The collaborative development of foundation models and biopharma product offerings with Mayo Clinic.
KEY QUOTES:
“At its core, Aignostics is a world-class machine learning company. The field is advancing so quickly that, in order to succeed, AI companies need to avoid flashy distractions, stay laser focused on the highest-quality science, and relentlessly innovate. Aignostics is doing just that and bringing a level of transparency and rigor to its biopharmaceutical clients that we think is truly unique.”
– Julian Zachmann from ATHOS
“We know that digital pathology, paired with the vast capabilities of AI, has immense potential to impact diagnosis and treatment for patients. Mayo Clinic is actively charting the new frontier of predictive and personalized care.”
– Jim Rogers, CEO of Mayo Clinic Digital Pathology
“2024 has been a pivotal year for us that has included a major strategic collaboration with Bayer and the launch of our first foundation model, RudolfV. With RudolfV, we’ve gained the ability to quickly develop cost-efficient algorithms that generalize to the real-world. Now with this new round of funding, we’re turning our most popular algorithms into products that will help usher in an era of truly generalizable AI for computational pathology.”
– Viktor Matyas, CEO and Co-Founder of Aignostics
